After the English High Court yesterday heard the second day’s arguments in the dispute between Actavis and Warner-Lambert concerning second medical use patents, two lawyers have told LSIPR that similar cases may be on the horizon.
The global market for products seeking to tackle counterfeit pharmaceutical and cosmetics packaging will reach more than $80 billion by 2020, according to a report.
Jazz Pharmaceuticals has sued Watson Laboratories for patent infringement in order to stop the company making a generic version of its flagship product Xyrem.
The US Court of Appeals for the Third Circuit has ruled that so-called ‘pay-for-delay’ settlements do not need to involve cash payments to be considered anticompetitive.
The English Court of Appeal has ruled in favour of Eli Lilly, finding that a patent covering its blockbuster lung drug Alimta would be infringed by a product proposed by Actavis, now Allergan.
Law firm Andrews Kurth has hired litigation attorney Matthew Dowd as a partner in its Washington, DC office.
The Life Sciences Law Forum opened today, June 25, with a lively panel on the implications of online technology for innovative companies in the sector, including the knock on effect for intellectual property rights.
A group of individuals has reportedly launched a class action lawsuit against Novartis to stop it enforcing a so-called ‘pay-for-delay’ settlement agreement with generic drug maker Sun Pharma centring on leukaemia drug Gleevec.
US law firm Nutter McClennen & Fish has boosted its intellectual property team in Boston with the appointment of Patrick Concannon as partner.
The US Food and Drug Administration, along with international police organization Interpol, has targeted more than 1,000 websites that sell fake, unapproved medicines and medical devices.